juni 25, 2020
SNF472 selectively inhibits pathological calcification by binding to hydroxyapatite crystals Palma, Spain and San Diego, USA, 25 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that data examining the mechanism of action of SNF472, Sanifit’s lead compound in development, has been published in the British Journal of...


Lundbeckfonden Ventures investerer i antidot mod blodfortyndere
8. juli 2020
Erfaren hjerneforsker i spidsen for The Brain Prize
30. juni 2020
Otte lovende yngre forskere får Lundbeckfonden fellowship
16. juni 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge